SLRN vs. TRDA, OCS, ANL, FULC, LXRX, ANNX, LRMR, TVTX, TBPH, and CRBP
Should you be buying Acelyrin stock or one of its competitors? The main competitors of Acelyrin include Entrada Therapeutics (TRDA), Oculis (OCS), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), Lexicon Pharmaceuticals (LXRX), Annexon (ANNX), Larimar Therapeutics (LRMR), Travere Therapeutics (TVTX), Theravance Biopharma (TBPH), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
Entrada Therapeutics has a net margin of 14.42% compared to Acelyrin's net margin of 0.00%. Entrada Therapeutics' return on equity of 9.73% beat Acelyrin's return on equity.
Acelyrin currently has a consensus price target of $21.67, indicating a potential upside of 403.88%. Entrada Therapeutics has a consensus price target of $21.00, indicating a potential upside of 38.34%. Given Acelyrin's higher possible upside, equities research analysts plainly believe Acelyrin is more favorable than Entrada Therapeutics.
87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Entrada Therapeutics has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acelyrin and Entrada Therapeutics both received 11 outperform votes by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 61.11% of users gave Acelyrin an outperform vote.
In the previous week, Acelyrin and Acelyrin both had 11 articles in the media. Acelyrin's average media sentiment score of 0.97 beat Entrada Therapeutics' score of 0.32 indicating that Acelyrin is being referred to more favorably in the media.
Summary
Entrada Therapeutics beats Acelyrin on 9 of the 14 factors compared between the two stocks.
Get Acelyrin News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acelyrin Competitors List
Related Companies and Tools
